#India #New Delhi #pharmaceuticals #CDMO #Akums Drugs

Akums's Expansion into Europe and the UK

Akums Drugs & Pharmaceuticals Ltd, recognized as the largest Contract Development and Manufacturing Organization (CDMO) in India, has recently strengthened its foothold in the European market, marking a significant milestone for both the company and India's pharmaceutical industry. Following the global trend towards increased collaboration in the pharmaceuticals sector, Akums is poised to become a key player in Europe and the UK by obtaining crucial certifications that enhance its competitive edge.

A Growing Global Presence

With the acquisition of European Union Good Manufacturing Practice (EU GMP) certification for two of its manufacturing facilities in India, Akums is set to cater to regulated international markets. The company has successfully renewed its certification for its solid oral dosage manufacturing site, dealing with tablets, capsules, and sachets, and secured new certification for its liquid manufacturing site, which produces solutions, syrups, and suspensions.

These certifications are a testament to Akums's commitment to maintaining international quality standards, thereby ensuring its capability to serve Europe's demanding pharmaceutical sector effectively. Akums aims to be recognized not only for its production volume but also for its adherence to global regulations and quality assurance protocols.

Strategic Market Entry

In a strategic move to penetrate the UK market, Akums has also secured its first approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Rivaroxaban, a widely used anticoagulant in the UK worth approximately USD 2.6 billion. This approval signifies Akums's formal entry into a vital segment of the British pharmaceutical industry, known for its stringent requirements and competitive landscape.

Mr. Sandeep Jain, the CEO of Akums, remarked, “We have established scale, compliance, and credibility in India, and we are determined to replicate this success internationally, especially in Europe and the UK. Our commitment to quality, reliability, and building long-term partnerships is unwavering.”

Furthermore, Mr. Sanjeev Jain, the Co-managing Director, highlighted, “Our production strength and regulatory discipline empower us to confidently enter regulated markets. This expansion is both calculated and ambitious.”

Innovation and Future Outlook

At the heart of Akums's successful expansion strategy lies a strong focus on research and development (R&D) driven by innovation. The company has developed an integrated R&D ecosystem that nurtures products from conception through commercial scaling, supporting a portfolio exceeding 20,000 product SKUs. In terms of capabilities, Akums has advanced R&D facilities covering over 60 dosage forms, inclusive of complex injectables and new drug delivery systems.

Current operations serve more than 1,500 clients globally, facilitated through 14 international standard manufacturing facilities—12 for formulations and 2 for Active Pharmaceutical Ingredients (APIs). With a collective production capacity surpassing 50 billion units annually, Akums is primed to meet the needs of a growing global healthcare market.

Conclusion

As India consolidates its standing as the 'Pharmacy of the World', Akums Drugs & Pharmaceuticals demonstrates how strategic international expansion complemented by adherence to stringent regulatory standards can lead to substantial growth opportunities. By leveraging its expertise and strong operational capabilities, Akums is not only enhancing its global footprint but is also paving the way for India's continued recognition in the global pharmaceutical landscape. With such ambitious yet measured steps, Akums is set to contribute significantly to enhancing healthcare outcomes in Europe and beyond.